On September 13, 2023, we filed a securities class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences, Ltd. et al., Case No. 1:23-cv-08097, on behalf of a class (“Class”) of individuals and entities that held common stock of Myovant Sciences, Ltd. (“Myovant”) as of the close of business on January 20, 2023 (“Class Period”), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and Securities and Exchange Commission Rule 14a-9 promulgated thereunder, in connection with the acquisition of Myovant by Sumitovant Biopharma Ltd. for an unfair price.
A copy of the complaint is available for download in the right sidebar.
Investors are hereby notified that not later than November 13, 2023, any member of the purported Class may move the Court to serve as lead plaintiff of the purported Class in this action.
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending action, please complete and submit the form below, and one of our attorneys will get back to you promptly.